StockData
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) stock

HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.01+0.05 (+0.15%)

Close on Nov 17, 2026Market cap $1.92BP/E 10.7Yield –

Harmony Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Harmony Biosciences's total debt was $153.96M at Jun 30, 2026. For fiscal 2025 it was $163.66M, down 8.7% from the year before. The highest annual figure on record is $194.25M in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$163.66M-8.7%
FY2024Dec 31, 2024$179.27M-7.4%
FY2023Dec 31, 2023$193.57M+1.0%
FY2022Dec 31, 2022$191.65M-0.2%
FY2021Dec 31, 2021$191.98M-1.2%
FY2020Dec 31, 2020$194.25M+98.3%
FY2019Dec 31, 2019$97.95M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$153.96M-10.5%
Q1 FY2026Mar 31, 2026$158.81M-9.6%
Q4 FY2025Dec 31, 2025$163.66M-8.7%
Q3 FY2025Sep 30, 2025$168.51M-7.8%
Q2 FY2025Jun 30, 2025$172.10M-7.7%
Q1 FY2025Mar 31, 2025$175.68M-7.5%
Q4 FY2024Dec 31, 2024$179.27M-7.4%
Q3 FY2024Sep 30, 2024$182.85M-7.2%
Q2 FY2024Jun 30, 2024$186.42M-2.6%
Q1 FY2024Mar 31, 2024$190.00M-0.8%
Q4 FY2023Dec 31, 2023$193.57M+1.0%
Q3 FY2023Sep 30, 2023$197.13M+2.8%
Q2 FY2023Jun 30, 2023$191.49M-0.2%
Q1 FY2023Mar 31, 2023$191.56M-0.2%
Q4 FY2022Dec 31, 2022$191.65M-0.2%
Q3 FY2022Sep 30, 2022$191.73M-0.2%
Q2 FY2022Jun 30, 2022$191.81M-1.9%
Q1 FY2022Mar 31, 2022$191.90M-1.5%
Q4 FY2021Dec 31, 2021$191.98M-1.2%
Q3 FY2021Sep 30, 2021$192.07M-0.4%
Q2 FY2021Jun 30, 2021$195.61M+99.7%
Q1 FY2021Mar 31, 2021$194.91M–
Q4 FY2020Dec 31, 2020$194.25M–
Q3 FY2020Sep 30, 2020$192.86M–
Q4 FY2019Dec 31, 2019$97.95M–

More Harmony Biosciences figures

See a number that looks wrong?